U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07678931) titled 'Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis' on June 25.
Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study aimed at evaluating the efficacy and safety of stapokibart in adolescent patients with seasonal allergic rhinitis, and observing the quality of life, Pharmakokinetics(PK), Pharmacodynamics (PD) characteristics, and immunogenicity of subjects.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Seasonal Allergic Rhinitis (SAR)
Intervention:
BIOLOGICAL: Stapokibart
subcutaneous injection
DRUG: Placebo
subcutaneous in...